Moderna Slashes Ten Percent of its Workforce, Huge Layoffs
Moderna, the once-revered pharmaceutical juggernaut behind one of the world’s most widely administered vaccines, has announced huge layoffs and will cut 10% of its workforce this year — a sobering sign that the company’s pandemic-era highs are firmly in the rearview mirror. The news arrived Thursday morning via an internal memo from CEO Stéphane Bancel, shedding light on a company now scrambling to recalibrate its strategy in a vastly different medical landscape.
$1.5 Billion in Layoffs as Revenues Crumble
The workforce reduction is just one component of a broader cost-cutting initiative aimed at reducing operating expenses by $1.5 billion by 2027. The urgency behind the move is clear: dwindling COVID-19 vaccine demand has left Moderna navigating uncertain waters, and its plans to pivot toward next-generation mRNA products are, at best, a long bet.
Bancel’s memo, while optimistic in tone, acknowledged the necessity of the pivot: “We’ve made significant progress by scaling down R&D as respiratory trials conclude, renegotiating supplier agreements, and reducing manufacturing costs.” Yet beneath the corporate polish lies a stark reality: Moderna’s golden goose—the standalone COVID-19 vaccine—is no longer yielding the expected results.
Delays Derail New Vaccine Strategy
The company had hoped that its new mRNA-based combination vaccines, particularly a COVID-flu hybrid, would carry it into a new era of profitability. However, regulatory delays and lackluster demand for its RSV (respiratory syncytial virus) vaccine have left those hopes hanging in the air. In May, Moderna confirmed that it doesn’t expect FDA approval for the combination shot until 2026, a full year later than it had once projected. The FDA’s demand for more robust late-stage data effectively rules out a 2025 rollout.
Investor Confidence Sinks Alongside Stock
Adding to the pressure is the shifting political landscape. Vaccine policy under U.S. Health Secretary Robert F. Kennedy Jr.—a noted vaccine skeptic—has injected new uncertainty into the regulatory and commercial outlook for all major pharmaceutical players, with Moderna particularly exposed given its singular reliance on mRNA-based vaccines.
Investors, for their part, are losing patience. Moderna’s stock is down 23% this year alone, and the decline is steep when viewed in the broader context: its share price has cratered more than 90% from the peak of the pandemic. Once a shining star of biotech innovation, Moderna now faces a tough reckoning—a brutal reminder that even giants can falter when the world moves on.
The road ahead will require more than new products and trimmed budgets. It will demand a reinvention. Whether Moderna can deliver on that remains an open question.
